☆ 4.6 Editorial Material

LRRK2-Targeting Therapies March Through the Valley of Death

MOVEMENT DISORDERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

Danna Jennings et al.

Summary: This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of the LRRK2 inhibitor BIIB122 in healthy participants and patients with Parkinson's disease. The results show that BIIB122 can significantly inhibit peripheral LRRK2 kinase and regulate the lysosomal pathway downstream of LRRK2.

MOVEMENT DISORDERS (2023)

添加到收藏夹

Article Neurosciences

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain

Enquan Xu et al.

Summary: This study explores the interaction between α-synuclein and LRRK2 in monocytes and the subsequent neuroinflammatory response. The study finds that pathological α-synuclein activates LRRK2 expression and kinase activity in monocytes, leading to their recruitment to the brain. The results suggest that inhibition of LRRK2 kinase activity may attenuate damaging pro-inflammatory monocyte responses in the brain.

MOLECULAR NEURODEGENERATION (2022)

添加到收藏夹

Article Clinical Neurology

Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk

Julie Lake et al.

Summary: This study conducted a large meta-analysis to investigate the association of LRRK2 rs76904798 with PD risk independently from LRRK2 coding variation, showing that rs76904798 remained significantly associated with PD after excluding carriers of relatively rare LRRK2 coding variants. The study also found that LRRK2 coding variants previously related to PD do not drive the 5' noncoding GWAS signal, suggesting an independent association of certain haplotypes with altered disease risk.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease

Shijie Wang et al.

Summary: This study measured the LRRK2 kinase substrate pT73-Rab10 in urine samples to understand the changes in LRRK2 kinase activity during iPD progression. The results showed that higher levels of pT73-Rab10 were associated with worse disease progression, providing initial insights into peripheral LRRK2-dependent Rab phosphorylation.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Impact of 100 LRRK2 variants linked to Parkinson’s Disease on kinase activity and microtubule binding

Alexia F Kalogeropulou et al.

BIOCHEMICAL JOURNAL (2022)

添加到收藏夹

Article Cell Biology

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease

Danna Jennings et al.

Summary: Mutations in LRRK2 are common genetic risk factors for Parkinson's disease. Inhibition of LRRK2 with DNL201 has shown positive effects in preclinical and clinical trials, improving lysosomal function and demonstrating safety and tolerability. Further development of LRRK2 inhibitors as a therapeutic modality for Parkinson's disease is warranted.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort

Nicole Bryant et al.

Summary: This study characterizes novel missense variants in the LRRK2 gene using whole-genome sequences and explores their relationships with known pathogenic and PD-linked variants. The results suggest that some high-pathogenicity variants cluster tightly in PD cases, and ultra-rare missense variants may have an important cumulative impact in increasing the number of individuals with LRRK2-linked PD.

HUMAN MOLECULAR GENETICS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation

Malidi Ahamadi et al.

Summary: Research on Parkinson's disease patients found that carriers of LRRK2 gene mutations have a slower progression rate of PD symptoms compared to non-carriers by nearly 60%, which provides important insights for the clinical application of LRRK2 inhibitors.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Clinical Neurology

R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils

Ying Fan et al.

Summary: This study found a significant increase in pRab10(Thr73) phosphorylation in carriers of the LRRK2 R1441G mutation, whereas the effect of the LRRK2 G2019S mutation was not statistically significant. Analysis of pRab10(Thr73) phosphorylation in post-mortem brain samples revealed high variability mainly due to the adverse effects of the peri- and post-mortem period on protein phosphorylation stability.

ACTA NEUROPATHOLOGICA (2021)

添加到收藏夹

Article Cell Biology

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans A Genome-Wide Association Study

Jia Nee Foo et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Neurosciences

Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients

Omar S. Mabrouk et al.

FRONTIERS IN NEUROSCIENCE (2020)

添加到收藏夹

Review Neurosciences

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics

Kaela Kelly et al.

FRONTIERS IN NEUROSCIENCE (2020)

添加到收藏夹

Article Neurosciences

Exosome markers of LRRK2 kinase inhibition

Shijie Wang et al.

NPJ PARKINSONS DISEASE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Caught in the act: LRRK2 in exosomes

Shijie Wang et al.

BIOCHEMICAL SOCIETY TRANSACTIONS (2019)

添加到收藏夹

Article Clinical Neurology

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Mike A. Nalls et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Article Genetics & Heredity

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

Emily A. King et al.

PLOS GENETICS (2019)

添加到收藏夹

Article Clinical Neurology

Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo

Elena Kozina et al.

BRAIN (2018)

添加到收藏夹

Article Neurosciences

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition

Kaela Kelly et al.

EXPERIMENTAL NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease

Kyle B. Fraser et al.

MOVEMENT DISORDERS (2016)

添加到收藏夹

Article Clinical Neurology

Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers

Kyle B. Fraser et al.

NEUROLOGY (2016)

添加到收藏夹

Article Biology

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

Martin Steger et al.

ELIFE (2016)

添加到收藏夹

Article Cell Biology

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

Reina N. Fuji et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

添加到收藏夹

Article Clinical Neurology

Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease

Lorraine V. Kalia et al.

JAMA NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic

Andrew B. West

MOVEMENT DISORDERS (2015)

添加到收藏夹

Article Clinical Neurology

Disease Penetrance of Late-Onset Parkinsonism A Meta-analysis

Joanne Trinh et al.

JAMA NEUROLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

LRRK2 secretion in exosomes is regulated by 14-3-3

Kyle B. Fraser et al.

HUMAN MOLECULAR GENETICS (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Determining target engagement in living systems

Gabriel M. Simon et al.

NATURE CHEMICAL BIOLOGY (2013)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Anthony A. Estrada et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Cell Biology

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

Zejuan Sheng et al.

SCIENCE TRANSLATIONAL MEDICINE (2012)

添加到收藏夹

Review Microbiology

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

Roland Nau et al.

CLINICAL MICROBIOLOGY REVIEWS (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Bridging the Valley of Death of therapeutics for neurodegeneration

Steven Finkbeiner

NATURE MEDICINE (2010)

添加到收藏夹

News Item Multidisciplinary Sciences

Translational research: Crossing the valley of death

Declan Butler

NATURE (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

AB West et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.